Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/NCOA2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/NCOA2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/NCOA2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/NCOA2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/NCOA2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/NCOA2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/NCOA2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/NCOA2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/NCOA2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/NCOA2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/NCOA2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004854528 | Skin | AK | response to steroid hormone | 73/1910 | 339/18723 | 4.51e-10 | 5.24e-08 | 73 |
GO:000762320 | Skin | AK | circadian rhythm | 51/1910 | 210/18723 | 2.80e-09 | 2.40e-07 | 51 |
GO:003292216 | Skin | AK | circadian regulation of gene expression | 23/1910 | 68/18723 | 1.18e-07 | 5.24e-06 | 23 |
GO:190165425 | Skin | AK | response to ketone | 43/1910 | 194/18723 | 7.32e-07 | 2.49e-05 | 43 |
GO:00325709 | Skin | AK | response to progesterone | 13/1910 | 37/18723 | 4.21e-05 | 6.70e-04 | 13 |
GO:004854529 | Skin | cSCC | response to steroid hormone | 135/4864 | 339/18723 | 1.34e-08 | 4.09e-07 | 135 |
GO:000762323 | Skin | cSCC | circadian rhythm | 89/4864 | 210/18723 | 1.55e-07 | 3.51e-06 | 89 |
GO:003292222 | Skin | cSCC | circadian regulation of gene expression | 37/4864 | 68/18723 | 5.65e-07 | 1.08e-05 | 37 |
GO:1901654112 | Skin | cSCC | response to ketone | 79/4864 | 194/18723 | 4.82e-06 | 7.06e-05 | 79 |
GO:004851123 | Skin | cSCC | rhythmic process | 110/4864 | 298/18723 | 1.83e-05 | 2.19e-04 | 110 |
GO:003257017 | Skin | cSCC | response to progesterone | 18/4864 | 37/18723 | 2.52e-03 | 1.43e-02 | 18 |
GO:000599610 | Skin | cSCC | monosaccharide metabolic process | 85/4864 | 257/18723 | 6.43e-03 | 3.14e-02 | 85 |
GO:000600610 | Skin | cSCC | glucose metabolic process | 66/4864 | 196/18723 | 9.75e-03 | 4.32e-02 | 66 |
GO:0048545113 | Thyroid | PTC | response to steroid hormone | 158/5968 | 339/18723 | 8.10e-09 | 2.00e-07 | 158 |
GO:003292219 | Thyroid | PTC | circadian regulation of gene expression | 43/5968 | 68/18723 | 1.03e-07 | 2.05e-06 | 43 |
GO:001931810 | Thyroid | PTC | hexose metabolic process | 108/5968 | 237/18723 | 6.42e-06 | 7.65e-05 | 108 |
GO:0048511111 | Thyroid | PTC | rhythmic process | 131/5968 | 298/18723 | 7.06e-06 | 8.33e-05 | 131 |
GO:000599614 | Thyroid | PTC | monosaccharide metabolic process | 115/5968 | 257/18723 | 9.36e-06 | 1.05e-04 | 115 |
GO:1901654113 | Thyroid | PTC | response to ketone | 90/5968 | 194/18723 | 1.56e-05 | 1.65e-04 | 90 |
GO:0007623111 | Thyroid | PTC | circadian rhythm | 96/5968 | 210/18723 | 1.74e-05 | 1.82e-04 | 96 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0491520 | Cervix | CC | Estrogen signaling pathway | 44/1267 | 138/8465 | 3.55e-07 | 3.97e-06 | 2.35e-06 | 44 |
hsa0491918 | Cervix | CC | Thyroid hormone signaling pathway | 33/1267 | 121/8465 | 3.11e-04 | 1.65e-03 | 9.78e-04 | 33 |
hsa04915110 | Cervix | CC | Estrogen signaling pathway | 44/1267 | 138/8465 | 3.55e-07 | 3.97e-06 | 2.35e-06 | 44 |
hsa0491919 | Cervix | CC | Thyroid hormone signaling pathway | 33/1267 | 121/8465 | 3.11e-04 | 1.65e-03 | 9.78e-04 | 33 |
hsa04919 | Colorectum | AD | Thyroid hormone signaling pathway | 51/2092 | 121/8465 | 1.71e-05 | 1.73e-04 | 1.10e-04 | 51 |
hsa049191 | Colorectum | AD | Thyroid hormone signaling pathway | 51/2092 | 121/8465 | 1.71e-05 | 1.73e-04 | 1.10e-04 | 51 |
hsa049192 | Colorectum | SER | Thyroid hormone signaling pathway | 40/1580 | 121/8465 | 1.02e-04 | 1.06e-03 | 7.67e-04 | 40 |
hsa04915 | Colorectum | SER | Estrogen signaling pathway | 38/1580 | 138/8465 | 6.51e-03 | 3.68e-02 | 2.67e-02 | 38 |
hsa049193 | Colorectum | SER | Thyroid hormone signaling pathway | 40/1580 | 121/8465 | 1.02e-04 | 1.06e-03 | 7.67e-04 | 40 |
hsa049151 | Colorectum | SER | Estrogen signaling pathway | 38/1580 | 138/8465 | 6.51e-03 | 3.68e-02 | 2.67e-02 | 38 |
hsa049194 | Colorectum | MSS | Thyroid hormone signaling pathway | 46/1875 | 121/8465 | 5.04e-05 | 4.97e-04 | 3.05e-04 | 46 |
hsa049152 | Colorectum | MSS | Estrogen signaling pathway | 48/1875 | 138/8465 | 4.23e-04 | 3.08e-03 | 1.89e-03 | 48 |
hsa049195 | Colorectum | MSS | Thyroid hormone signaling pathway | 46/1875 | 121/8465 | 5.04e-05 | 4.97e-04 | 3.05e-04 | 46 |
hsa049153 | Colorectum | MSS | Estrogen signaling pathway | 48/1875 | 138/8465 | 4.23e-04 | 3.08e-03 | 1.89e-03 | 48 |
hsa049198 | Colorectum | FAP | Thyroid hormone signaling pathway | 41/1404 | 121/8465 | 2.28e-06 | 4.28e-05 | 2.60e-05 | 41 |
hsa049199 | Colorectum | FAP | Thyroid hormone signaling pathway | 41/1404 | 121/8465 | 2.28e-06 | 4.28e-05 | 2.60e-05 | 41 |
hsa0491910 | Colorectum | CRC | Thyroid hormone signaling pathway | 35/1091 | 121/8465 | 2.05e-06 | 6.85e-05 | 4.64e-05 | 35 |
hsa049154 | Colorectum | CRC | Estrogen signaling pathway | 29/1091 | 138/8465 | 4.83e-03 | 2.66e-02 | 1.80e-02 | 29 |
hsa0491911 | Colorectum | CRC | Thyroid hormone signaling pathway | 35/1091 | 121/8465 | 2.05e-06 | 6.85e-05 | 4.64e-05 | 35 |
hsa049155 | Colorectum | CRC | Estrogen signaling pathway | 29/1091 | 138/8465 | 4.83e-03 | 2.66e-02 | 1.80e-02 | 29 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NCOA2 | SNV | Missense_Mutation | | c.2933N>A | p.Gly978Glu | p.G978E | Q15596 | protein_coding | tolerated(0.11) | possibly_damaging(0.621) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
NCOA2 | SNV | Missense_Mutation | | c.826N>T | p.Leu276Phe | p.L276F | Q15596 | protein_coding | deleterious(0.01) | benign(0.086) | TCGA-BH-A0W7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
NCOA2 | SNV | Missense_Mutation | | c.703N>A | p.Pro235Thr | p.P235T | Q15596 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E9-A1N4-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
NCOA2 | SNV | Missense_Mutation | | c.254A>T | p.Glu85Val | p.E85V | Q15596 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
NCOA2 | SNV | Missense_Mutation | novel | c.109N>T | p.Arg37Cys | p.R37C | Q15596 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-UL-AAZ6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | herceptin | SD |
NCOA2 | insertion | Frame_Shift_Ins | novel | c.2845_2846insGGTTTAGAAC | p.Met949ArgfsTer68 | p.M949Rfs*68 | Q15596 | protein_coding | | | TCGA-E9-A1NI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
NCOA2 | SNV | Missense_Mutation | rs373466036 | c.3137N>T | p.Ala1046Val | p.A1046V | Q15596 | protein_coding | tolerated(0.31) | benign(0.007) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NCOA2 | SNV | Missense_Mutation | rs777306143 | c.2485N>A | p.Ala829Thr | p.A829T | Q15596 | protein_coding | tolerated(0.25) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NCOA2 | SNV | Missense_Mutation | novel | c.1830N>T | p.Lys610Asn | p.K610N | Q15596 | protein_coding | deleterious(0.02) | benign(0.138) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NCOA2 | SNV | Missense_Mutation | rs375519556 | c.3389C>T | p.Ala1130Val | p.A1130V | Q15596 | protein_coding | deleterious(0.02) | benign(0.011) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |